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Abstract 
 Recent studies have shown that a single asymptomatic dose exposure to the nerve 
agent sarin in mice leads to long term cardiac dysfunction.  This study looked at 
immediate and delayed treatment therapies post sarin exposure on cardiac function.  
Heart function and structure  were studied using electrocardiography (EKG) and 
histological/immunochemical techniques (staining with hematoxylin/eosin and brain 
natriuretic peptide, BNP).  Male C57BL/6J mice were injected with sarin (0.4LD50) 
followed immediately with atropine/2PAMCL (standard nerve agent treatment) or at 9 
wks with β adrenergic agonist/antagonist. Measurements were made ~ 3 months post 
sarin.  Mice given atropine/2PAMCL showed significantly higher cardiomyocyte size 
and BNP levels than controls (p = 0.001). EKGs showed T-wave anomalies. These 
results are indicators of cardiac insult.  The second treatment groups received 
isoproterenol or propranolol  (β agonist and antagonist, respectively, sc infusion for 2 
wks) after onset of cardiac remodeling. Isoproterenol increased heart weight (p = 0.0018) 
and myocyte size and caused inverted T-waves. Propranolol treated mice showed only T-
wave depression with no change in heart size.  Results suggest 1) standard 
atropine/2PAMCL treatment does not prevent sarin-induced cardiac dysfunction and in 
fact may cause pathologies and 2) β agonist stimulation exacerbates the cardiac response 
to sarin suggesting possible interactions between sarin and stress exposure. 
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IMMEDIATE AND DELAYED DRUG THERAPY EFFECTS ON LOW DOSE SARIN 
EXPOSED MICE MYOCARDIAL PERFORMANCE 
 
 
I. Introduction 
Historical Use and Future Concerns of Sarin 
 Sarin is a highly lethal neurological toxin which was first created in 1938. It is a 
colorless and odorless liquid which rapidly evaporates into the gaseous state.  The 
Germans weaponized and stockpiled sarin during WWII, along with other chemical 
agents, but never employed them.  Since WWII, there have been multiple confirmed and 
suspected uses of chemical warfare agents (CWA) in conflicts around the world; Yemen 
Civil War (1963-1967), Soviet’s in Afghanistan (1979-1989), Iran-Iraq War (1980-1988), 
Iraq against the Kurds (1988), and Libya against Chad (1987) (Salem, et al. 2008).  In all 
of these military actions nerve agents were among those chemical agents suspected of 
being employed, additionally the perpetrators of the chemical agent use were all national 
governmental organizations.  In the mid 90’s chemical agent attacks no-longer became 
the sole domain of nation states.  In 1994 and 1995 a cult group known as Aum 
Shinrikyo, employed sarin against Japanese government and civilian targets leading to 
wide spread civilian casualties (Committee on Gulf War and Health: Updated Literature 
Review of Sarin 2004, Ferguson 2009).  In 1998 Bin Laden stated it was a religious duty 
to acquire Weapons of Mass Destruction (WMD) in defense of Muslims.  In 2003, 
Shaykh nasir bin Hamid al-Fahd, a young cleric wrote a religious paper entitled “A 
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Treatise on the Legal Status of Using Weapons of Mass Destruction”, further defending 
the “right” of terrorists to acquire and use WMDs (Ferguson 2009).  As a result, 
increasing efforts have been undertaken to be able to better protect and respond to both 
military and civilian causalities from a nerve agent attack.  However, treatment and 
detection capabilities are still based on symptomatic dose levels, which, leaves gaps in 
our ability to properly identify and treat casualties to low level asymptomatic exposure to 
nerve agent.   
 Sarin and nerve agents have again become a topic for research in the last two 
decades following the unintentional exposure of U.S. Soldiers in 1991 to low levels of 
nerve agent following the destruction of the Khamisiyah munitions site in Iraq (see 
Figure 1).   
 
 
 
Figure 1.  Plume Models for the Demolition of Bunkers at Khamisiyah, 12 March 1991 
(Persian Gulf War Illnesses Task Force 1997) 
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According to the Committee on Gulf War and Health estimates, nearly 90,000 Soldiers 
may have been exposed to sarin and/or cyclosarin following the demolitions at the 
Khamisiyah site (Committee on Gulf War and Health: Updated Literature Review of 
Sarin 2004).  Due to this potential exposure to sarin and other nerve agents, they were 
implicated as possible etiological agents in those suffering from Gulf War Illness (GWI). 
Theses chemical agents were therefore recommended by a Presidential Advisory 
Committee to be the subject of extensive investigation by agencies that treat those 
veterans (Couzin 2004, McDonough and Romano 2008) 
Problem Statement 
 Past research and medical information focused on understanding symptomatic 
large dose exposure affects from nerve agents, little to no information is available 
concerning asymptomatic low dose and late-onset effects from nerve agent exposure.  
With the possibility of personnel exposures at these low levels occurring near the attack 
site, a better understanding is needed on possible health effects of low dose exposure 
levels.  Additional understanding of these possible health effects could also lead to 
changes in current mission oriented protective posture (MOPP) guidance for military 
personnel.  This is due to the fact that current guidance only considers doses which 
present clinical signs of nerve agent exposure as relevant.  Also, current detectors are 
unable to detect agents below symptomatic levels.  Further understanding of late-onset 
symptoms and affects on personnel could also lead to changes in long term treatment of 
nerve agent exposure victims. 
 Recent studies by Morris and Horenziak focused on the long term cardio-toxic 
effects following a single asymptomatic dose (Morris, Key and Farah 2007, Horenziak 
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2010).  Initial findings by Morris et al. linked autonomic changes with the heart in mice, 
after exposure to low doses of nerve agent, which showed increases in heart rate 
variability, (Morris, et al. 2007).  In the recent study by Horenziak, data indicates delayed 
onset of morphology and reduced cardiac function of mice exposed to low doses of the 
nerve agent, sarin.  It was also shown that, even with normal cardiac function during 
basal conditions, cardiac function showed reduced levels of performance when stressed 
(Horenziak 2010). 
A Review on the Chemistry and Toxicology of Sarin 
 Sarin, chemical name isopropyl methylphosphonoflouridate (military designation 
– GB), belongs to a class of chemical compounds known as organophosphates.  
Organophosphates are chemical toxins that inhibit acetyl cholinesterase (AChE) and are 
widely used as commercial pesticides and CWA.   Sarin’s toxic effect is the result of its 
ability to phosphorylate the serine hydroxyl residue in the active pocket of AChE, 
forming either a phosphoric or phosphonic acid ester which is extremely stable.  This 
reaction irreversibly deactivates or “inhibits” the enzyme (Abou-Donia 2003).  In sarin’s 
case the irreversible binding or “aging” is a process which can occur that permanently 
binds the sarin to AChE thus preventing reactivation of the enzyme (CDC 2007).  As 
AChE becomes inhibited acetylcholine (ACh), a cholinergic neurotransmitter, builds up 
at receptor sites causing overstimulation.  Overstimulation occurs at the central and 
peripheral cholinergic sites in smooth muscles, skeletal muscles, most exocrine glands, 
the central nervous system (CNS), and the cardiac system (e.g. central and ganglionic 
afferents), (Horenziak 2010). 
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 Stimulation of muscarinic receptors at the smooth muscle level causes miosis, 
bronchioconstriction, vasodialation, increased peristalsis, and reduced heart rate at 
smooth muscle level.  At exocrine glands, it causes secretions in the lung, nasal, oral, and 
sweat glands. Clinical effects due to nicotinic receptor overstimulation at skeletal muscles 
are fasciculation, twitching, flaccid paralysis and stimulation of autonomic ganglia 
leading to tachycardia and hypertension. The CNS has both muscarinic and nicotinic 
receptors and overstimulation leads to seizures and can cause death; whereas, a mild 
exposure leads to variety of symptoms which include forgetfulness, bad dreams, 
insomnia, and the inability to concentrate (USAMRID 2007, Horenziak 2010).  
 Sarin affects the cardiovascular system in a complex manner; effects are due to 
actions on both ganglion and postganglionic consequences of accumulated ACh on the 
heart and blood vessels. The overall acute effect on the heart depends on the relative 
prevalence of sympathetic or parasympathetic effects. Cholinergic effects from ACh 
suppress vagal tone resulting in a decreased refractory period and conduction time at 
sinoatrial (SA) and atrioventricular (AV) nodes. An excess of Ach also affects the 
muscarinic ACh M2 receptors in heart leading to negative chronotropic and ionotropic 
effects.  Thus, ACh creates contradicting excitatory effects on parasympathetic 
ganglionic cells in the face of the inhibitory effects of the sympathetic ganglia.  The 
build-up of ACh elicits similar excitatory, followed by inhibitory, effects at the medullary 
vasomotor and cardiac centers. In severe ACh accumulation, hypoxia resulting from 
bronco-constriction also affects the cardiovascular system by reinforcing sympathetic 
tone, while ACh induced epinephrine release from adrenals leads to increased heart rate.  
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As a result, sarin induces bradycardia, tachycardia, and arrhythmias in the heart that can 
lead to spontaneous cardiac failure (Taylor 2001, Horenziak 2010).  
 To counteract nerve agent exposure, the medical and military community uses a 
two or three drug combination to treat affected persons.  Each drug has a specific affect 
on the patient which when used in combination can counter the acute effects of nerve 
agent exposure.  The drugs are atropine, an anticholinergic compound, pralidoxime 
chloride (2PAMCL), an oxime, and diazepam, an anticonvulsant.  Atropine/2PAMCL or 
MARK I will be used throughout the paper to denote the use of the two drug antidote 
sequence atropine plus parlidoxime chloride.  Atropine (the primary drug treatment for 
nerve agent exposure) is used to block excess Ach at peripheral muscarinic sites which 
results in a decrease in secretions and an increase in heart rate.  2PAMCL is used to 
reactivate affected Ache and acts by binding to the nerve agent that is attached to the 
Ache and then breaks the nerve agent-enzyme bond, restoring the Ache to full 
functionality.  This reaction is only possible if the nerve agent has not “aged”, if aging 
has occurred the Ache cannot be restored to functionality and Ache levels can only be 
increased by new production in the body, typically at the rate of about 1% a day.  
Diazepam is only used in cases of extreme nerve agent exposure to prevent brain injury 
caused by convulsions and seizures (USAMRID 2007). 
Research Objectives/Hypothesis 
 The research objectives for this study are two-fold.  First, is to evaluate the 
effectiveness of immediate treatment after exposure with atropine/2PAMCL to prevent 
cardiac remodeling. Second, is to study the effects of β receptor agonists and antagonists 
on cardiac performance and morphology, with no prior treatment, after sarin induced 
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cardiac remodeling has occurred.  These studies will help to create a better understanding 
of the long term effects expected to manifest following a low-dose sarin exposure with 
the use of the MARKI antidote kit in troops or the general population.   
Additional Specific Aims are: 
 Determine the time course of cardio toxic actions of sarin in mice.  Using an 
asymptomatic dose of sarin, follow the EHCO and ECG changes up to 8 weeks 
post exposure in mice with and without nerve agent antidote treatment 
(atropine/2-PAMCL).  This will help to test the hypothesis that prompt treatment 
with nerve agent antidote will prevent long cardiac remodeling in exposure 
victims.  
  
 Determine the effect of sarin combined with a hypertrophic stimulus, 
isoproterenol.  The hypothesis is that there will be an exacerbation of the cardio 
toxic effects of sarin.   
 
 Determine the effects of the blockade of β-adrenergic function and inhibition of 
central sympathetic outflow on the cardio toxic effects of sarin.  The hypothesis is 
that treatment with a β-blocker will help reverse the cardiac remodeling induced 
by an acute low dose exposure to sarin.   
 
Experimental Design 
 Male mice (C57BL6 strain) were injected on two consecutive days by WSU 
personnel and broken into six groups of 10 mice each.  The groups were; control, 
control+atropine/2PAMCL, 0.4LD50 sarin, 0.4LD50 sarin+atropine/2PAMCL, groups five 
and six were given 0.4LD50 of sarin and then further broken down into three groups 
which were given saline, isoproterenol, and propranolol respectively.  
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Table 1.  Study Groups 
 
 
 
 
 Each group was studied using both in vivo (ECG analysis, echocardiography 
(ECHO)) and histological techniques (brain natriuretic peptide (BNP), hematoxylin and 
eosin (H&E), and Masson Trichrome) to determine if there were any changes in cardiac 
function or any cardiac remodeling occurring.  At various points post exposure a short-
acting β-1 specific agonist (dobutamine) was used to study cardiac performance during 
elevated cardiac output conditions.  Various ECHO and ECG measurements were taken 
to measure left ventricular structure and cardiac performance before and after a 
dobutamine stress test.  At the end of each study period the mice were sacrificed and 
relevant tissues and organs were taken for follow-on histological analysis. 
 
  
Sarin 
Injection
Recovery Week 3 Week 7 Week 9 Week 11
Control x x x,y x,y,z
Sarin x x x,y x,y,z
Control+Atropine/2PAMCL x x x,y,z
Sarin+Atropine/2PAMCL x x x,y,z
Sarin+Saline x x x,y x,y x,y,z
Sarin+Isoproterenol x x x,y x,y x,y,z
Sarin+Propranpolol x x x,y x,y x,y,z
x - Body Weight Measurements Taken
y - ECG Mesurements Taken
z - Sacrifice 
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II. Literature Review 
Introduction 
 Recent studies by Morris Lab at Wright State University (WSU) have examined 
cardiac morphology and other changes to the hearts of mice after acute asymptomatic 
doses of sarin (Morris, Key and Farah 2007, Horenziak 2010).  This study looked at 
effects of atropine/2PAMCL antidote treatment and various β adrenergic drug treatments 
on mice, after asymptomatic dose exposure levels to sarin.    
Animal Considerations 
 Mice, unlike humans have higher levels of carboxyl esterase which has been 
shown too rapidly and degrade sarin.  These elevated levels of carboxyl esterase change 
the normal dose response curve in mice compared to that of humans (Li, et al. 2005, 
Jokanovic, et al. 1996).  This natural protective nature of carboxyl esterase requires that 
the mice be dosed on consecutive days.  The first dose is used to consume the 
endogenous carboxyl esterase in the mice which then allows the second dose to follow a 
dose response curve that more accurately reflects that seen in humans.  To verify that the 
desired level of acetyl cholinesterase inhibition has been achieved in the mice, serum 
cholinesterase assays are performed by Dr. Lucot following a protocol used by Sidell et 
al (Sidell and Borak 1992).  
Choice of Anesthesia and Expected Effects 
 Conducting non-invasive observation techniques to measure cardiac performance 
requires taking into account affects on the mice due to the techniques used and the data 
that is to be collected.  There have been well documented differences between conscious 
and unconscious mice in ECHO and ECG which are used to measure cardiac 
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performance.  Studies which used ECHOs have shown a decrease in heart rate variability, 
fractional shorting, and ejection fraction in unconscious mice (Tan, et al. 2003, Stein, et 
al. 2005, Roth, et al. 2002).  Additionally, ECG recordings have shown increases in QT 
and PR intervals and decreases in heart rate (Chavesa, et al. 2003).    
 Despite the potential drawbacks with using sedatives, it has been shown that they 
help to reduce stress in the mice, which, should lead to significantly reduced variabilities 
seen in ECHOs when compared to conscious mice; this is due to differences in stress 
created in the mice from the restraints or the handling training the mice received (Tan, et 
al. 2003).  Other research by, Kramer et al. has shown that using restraints on mice leads 
to increases in body temperature, blood pressure, heart rate, plasma levels, and variable 
responses to pharmaceutical treatments (Kramer, et al. 2001).  Additionally, issues 
related to high heart rates from stress and transducer placement due to small movements 
in conscious mice have led to failures in obtaining quality ECHO recordings (Roth, et al. 
2002, Tan, et al. 2003).  Issues associated with taking ECG recordings in conscious mice 
include being able to only take short time interval readings and the development of 
movement artifacts in the recordings.  To prevent issues with lead placement on the mice 
the ECG probes are typically implanted in the mice or require restraints, both of which 
lead to increases in time and cost verses using anesthesia (Chavesa, et al. 2003).     
 Isoflurane (ISF) is the agent of choice for animal research and has been shown in 
multiple research papers to have the least affects on the heart compared to other 
anesthesia during ECHO and ECG analysis (Tan, et al. 2003, Stein, et al. 2005, Roth, et 
al. 2002, Chavesa, et al. 2003).  Another benefit of ISF is that it has a more rapid onset 
time and provides more reproducible results than other which make it preferable for short 
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lived experiments (Stein, et al. 2005).  Due to inherent advantages of ISF over conscious 
mice and its extensive successful use at WSU’s Live Animal Research (LAR) lab in 
previous sarin related research it was chosen for use in this experiment in order to 
maintain procedural consistency.  All mice were treated with ISF in the same manner to 
conduct ECHO and ECG analysis, as such, there is expected to be little to no effect on 
the procedural outcomes.  
Body Temperature Regulation Concerns 
 Research has shown that mice are unable to regulate their body temperature when 
they are sedated; this can lead to significant fluctuations in heart rate and cardiac function 
(Hartley, et al. 1995, Hartley, et al. 2002).  Changes in performance can occur with 
changes as little as 4
0
C (Swoap, et al. 2004).  To minimize issues with changes in body 
temperature, the room was temperature controlled at (22
0
C ± 1
0
C); additionally, thermal 
pads (Brain Tree Scientific, Delta Phase Isothermal Pad for 37
o
C (model # 39DP)) were 
used to maintain body temperature at 32
0
C ± 2
0
C during the in vivo monitoring process.   
Dobutamine Stress Testing 
 Cardiac function can change depending upon whether the subject’s heart is 
experiencing normal (unstressed) or increased (stressed) cardiac output conditions.  It is 
therefore important to test cardiac function in both states to evaluate overall cardiac 
function.  Dobutamine is a drug that is commonly used in cardiac stress testing to study 
cardiac function in a stressed state.  It acts on the β1 adrenergic site and is a preferred 
drug for this type of testing due to its strong but short lived actions on the heart 
(Anderson, et al. 2008, Daly, et al. 1997, Mertes, et al. 1993, Shaheen, et al. 1998).  The 
duration of the tachycardia lasts for approximately 25 minutes and creates an oxygen 
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supply-demand mismatch in the heart by increasing myocardial oxygen demand 
(Weissman, et al. 1996, Wiesmann, et al. 2001).  Due to the preferential nature of 
dobutamine to bind to the β1-adrenoreceptors, using it to conduct the stress test can 
provide information on the overall function of the receptor cascade by using ECG and 
ECHO analysis to observe the changes (Anderson, et al 2008, Weissman, et al. 1996).  
An important consideration in using dobutamine for the stress testing is that in low doses 
it has not been shown to have any long lasting effects on the heart.  However, if it is 
administered continuously over a period of time (seven days) it has been shown to 
increase fibrosis and lead to hypertrophy in the heart (Anderson, et al. 2008).  The mice 
were given dobutamine during weeks; 3, 7, 9, and 11 as part of the stress test in doses of 
1mg/kg body weight (approximately 30µg/mouse).  The low dose levels and time interval 
in-between injections should prevent any long-term damage due to the dobutamine 
stimulation of the hearts. 
Noninvasive In Vivo Measurements  
Echocardiograms 
 Echocardiography is a well known and widely used noninvasive procedure to 
measure and determine aspects of overall cardiac function in humans and animals.  The 
most widely used imaging techniques are the 2D, M-mode, and Doppler.  Using these 
modes it is possible to measure heart rate, wall thickness, left ventricular area, and the 
myocardial performance index (Horenziak 2010).  While ECHO was performed during 
each stage of the experiment, equipment data recording failures prevented proper analysis 
of the data and thus precluded its use in this study. 
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Electrocardiograms (ECG) 
 Electrocardiography has been widely used in murine research for over 70 years to 
look at electrical impulses of the (Hartley, et al. 2002, Wehrens, et al. 2000).  The 
characteristic readout of ECGs is due to the successive electric impulse propagation 
throughout the heart.  The beginning of the heart beat occurs at the sinus node then 
rapidly moves through the atria, which is indicated by the P wave.  The following PR 
interval represents the movement of the impulse to the AV node.  The ventricular 
contraction is shown via the QRS complex that immediately follows the PR interval.  
Atria repolarization occurs during ventricular contraction, but does not show due to the 
height and intensity of the QRS complex.  The following ST segment represents 
ventricular relaxation and is then followed by the T-wave which represents ventricular 
repolarization.  The initial impulse then dissipates, which is shown by the return to the 
iso-electric line (see Figure 2), (Ramos 2003, Geiter 2007, Horenziak 2010). 
 
 
 
Figure 2.  Typical Human ECG 
(This image is licensed for unrestricted redistribution 
(Atkielski 2007)). 
          
 
 
Figure 3.  Typical Mouse ECG Illustrating the 
Difference in the T-wave when Compared to the 
Human ECG 
T-wave merged
with QRS
T-wave peak
T-wave end
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 The ECG of mice has one distinct difference from that of humans.  In mice the T-
wave is merged with the end of the QRS complex which results in noticeable lack of a ST 
segment (see Figure 3), (Wehrens, et al. 2000, Mitchell, et al. 1998, London 2001).  The 
T wave in mice begins above the iso-electric line and then falls below it and is followed 
by a gradual return back to the iso-electric line (Mitchell, et al. 1998, Horenziak 2010, 
Wehrens, et al. 2000, London 2001).  The T-wave is typically the first place on an ECG 
that changes from its normal pattern when issues occur in cardiac performance.  Cardiac 
insults can result in T-wave inversions, ST depression, elongation of the QT interval, or 
even a lack of a T-wave (Geiter 2006).  By analyzing changes to and anomalies on the 
ECG, any number of dysfunctions in the cardiovascular system can be observed and 
therefore treated.    
In Vitro/Histological Markers  
Utility of BNP Measurements  
 In the recent study by conducted by Horenziak, brain natriuretic peptide (BNP) 
levels were significantly increased in sarin treated mice.  This peptide was first observed 
in pig brains (hence the name) but is only expressed in the ventricles of humans and mice 
(Brain natriuretic peptide 2010).  The presence of increased BNP levels has been shown 
to occur after the heart undergoes a serious insult and hypertrophy has occurred (He, et 
al. 2001).  Brain natriuretic peptide is created and stored in ventricular cells and increases 
in response to cardiac stress and are a sign of heart failure, hypertrophy, or any number of 
stresses to the heart (Goetze, et al. 2009, Yasuno, et al. 2009).  The different natriuretic 
peptides have also been shown to have protective effects against hypertrophy in vitro 
when released from the cells (London 2006).  Brain natriuretic peptide exerts its 
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natriuretic, diuretic, and vasorelaxant effects through activation of its common receptor 
Natriuretic Peptide Receptor A (NPRA) (Kawakami, et al. 2010, London 2006).  Another 
important aspect of BNP is that it is expressed in fetal ventricles but is not present in 
significant amounts in adult mice ventricles (Scott, et al. 2009).  These characteristics of 
BNP mean that it can serve as an excellent marker of cardiac insult to the murine heart, as 
such its presence or lack thereof should provide an indication of whether 
atropine/2PAMCL treatment, post sarin exposure can protect the heart. 
Hematoxylin and Eosin (H&E) Staining 
 Hematoxylin and eosin staining is a commonly used technique in preparation of 
histology slides.  Hematoxylin and eosin stains nuclei purple to blue and the rest of the 
cell pink to red (Eroschenko 2008).  As such, the H&E stain provides important 
information about the nuclei and muscle fiber arrangement and cell size when heart 
sections are examined under a microscope (Horenziak 2010).  For this study the H&E 
stained slides were used to obtain an estimate of average cell size by taking a ratio of 
nuclei to cell area.      
Drug Therapies  
Atropine+2PAMCL 
 Atropine plus 2PAMCL is the standard treatment for nerve agent poisoning by 
both the military and emergency medical personnel.  It is administered via the Mark-I kit 
which has 2mg of Atropine and 600mg of 2PAMCL (Meridian Medical Technologies, 
Inc. 2003).  After exposure to a nerve agent the Mark I kit can be administered up to three 
times prior to treatment by medical personnel (USAMRID 2007).  The number of Kits 
used depends upon the severity of the poisoning; current protocol is not to use the kits if 
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the person is asymptomatic (USAMRID 2007, New York State Department of Health 
Bureau of Emergency Medical Services 2003).   
 Atropine acts as a competitive receptor antagonist, blocking the effects of ACh at 
the muscarinic sites preventing it from lowering the heart rate to dangerous levels after 
nerve agent exposure (USAMRID 2007, Brown and Taylor 2001).  The second half of 
the Mark I kit, 2PAMCL, acts as a cholinesterase reactivator by rehydrolyzing the 
enzyme allowing it to resume hydroxylation of the ACh, thus deactivating it as 
neurotransmitter (Parkinson 2003, Hoffman and Taylor, Neurotransmission: The 
Autonomic and Somatic Motor Nervous Systems 2001).  The intent of this research is to 
determine whether a small dose of the atropine/2PAMCL nerve agent treatment kit can 
have a protective effect on the cardiac tissue post exposure to sarin. 
Propranolol 
 Propranolol is a Class II antiarrhythmic drug which acts as a β-adrenergic receptor 
blockade (Ramos, et al. 2003).  Major benefits of propranolol are reduced heart rate, 
decrease in myocardial oxygen demand, and reduction in arterial blood pressure (Kerins, 
et al. 2001).  Recent studies have shown that the antihypertrophic effects of propranolol 
are independent of its β-adrenergic blockading ability.  These effects in rats were found 
when doses of 40 and 80 mg/kg per day were given over a 17 day period (Marano, et al. 
2002).   
Isoproterenol 
 Isoproterenol is a non selective β-adrenergic agonist which also has a low affinity 
for α-adrenergic receptors.  As a catecholamine, effects of isoproterenol on the heart lead 
to increased heart rate, increased myocardial oxygen demand, and possible electrolyte 
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alterations (Ramos, et al. 2003, Hoffman 2001).  Cardiac researchers have been using 
isoproterenol for around fifty years as a means to induce hypertrophy in small animals 
(Anderson, et al. 2008).  By treating the sarin treated mice with isoproterenol and with a 
β-blocker (propranolol) it is hoped that insight into mechanisms by which sarin acts on 
heart can be found. 
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III. Methodology 
Animal Experimental Protocol 
 Sixty-two C57BL/6J male mice were used in two studies (41 in the atropine study 
and 21in the β adrenergic drug therapy study).  They were individually housed at 22oC on 
a 12:12 light-dark cycle at the WSU LAR.  Forty-two mice were treated with sarin nerve 
agent on two consecutive days.  The other 20 mice were treated with saline and acted as 
the control mice.  In-vivo cardiac performance measurements were taken along with 
weight during weeks three, seven, nine, and 11 post sarin exposure. 
 Compared to humans, mice have a higher level of blood cholinesterase which 
interacts with and consumes nerve agent, preventing the agent from acting on the nervous 
system and organs.  To ensure proper dose response, mice were treated with sarin twice; 
the first dose metabolically consumes the cholinesterase in the blood followed by a 
second injection 24hrs later which exerted the inhibitory response that was studied.  
Twenty-four hours after the final injection the blood cholinesterase levels were measured 
using a standard assay developed at WSU (Horenziak 2010).   Following the last dose of 
sarin, 10 mice from the control group and 10 mice from the sarin group were given an 
atropine/2PAMCL treatment of 10 and 25 mg/kg respectively.   
 Two separate studies were conducted; the first (referred to as the Atropine Study) 
looked at antidote treatment effects following low dose exposure to sarin, which 
consisted of control, control+atropine/2PAMCL, 0.4LD50 sarin, and 0.4LD50 
sarin+atropine/2PAMCL groups.  The control and sarin groups from the first study had 8 
and 7 mice surgically implanted with ECG telemetry probes from Data Science 
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International (model TA-F10) to record continuous ECG data after the week three in vivo 
analysis.  The probes were set to record for 15 minutes every hour for 24hrs.   
 The second (referred to as the β adrenergic drug therapy study) looked at various 
drug treatments on sarin exposed mice, which consisted of 0.4LD50 sarin+saline, 0.4LD50 
sarin+isoproterenol, and 0.4LD50 sarin+propranolol groups.  These mice were evaluated 
at week nine and then micro-osmotic pumps (model 1007D from Alzet®) were implanted 
to administer doses of saline (20mg/kg/day), isoproterenol (30mg/kg/day), and 
propranolol(20mg/kg/day) over a two week period.  At the end of the two weeks (week 
11) the mice were evaluated in vivo and then sacrificed. 
Tissue Collection and Histology Sectioning 
 In the seventh week the atropine study mice were sacrificed and in week 11 the β 
adrenergic drug therapy study mice were sacrificed via decapitation and tissue samples 
were collected and preserved.  After the mice were decapitated the heart was collected, 
weighed, and then placed into a phosphate buffered saline (PBS) solution.  Each heart 
had its apex removed and the heart was placed in a 4% paraformaldehyde (PFA) solution 
and stored at 4
o
C for 48 hours.  Following soaking for 48 hours in the PFA the tissues 
were removed and fixed in 20% sucrose, 4% PFA solution.  They hearts were then stored 
for another 24 hours at 4
o
C and then transferred to a -80
o
C freezer where they were stored 
until they were sent to AML Laboratories for heart sectioning.  Each mouse was 
sectioned into five slides with two heart sections per slide.  One of the slides from each 
mouse was stained with Hematoxylin and Eosin (H&E) by AML.  Additionally, AML 
stained one slide from each group with masson’s trichrome which allows for the study of 
collagen fibers. 
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Hematoxylin and Eosin Analysis Methods 
 Hematoxylin and eosin staining is a common staining technique used to highlight 
nuclei from cell tissue.  In this experiment H&E stained slides were analyzed to compare 
overall cell size.  All H&E staining was conducted by the AML personnel at the same 
time as the heart sectioning.  They were used to conduct cell size analysis via nucleus to 
pixel area ratio.  The H&E stained slides were analyzed using a slightly modified version 
of a protocol that was used by Horenziak.  The slides were viewed under a Leica 
Microsystems® DMR microscope at 20X Magnification (see Figure 4). 
 
 
 
Figure 4.  H&E Stained Slide at 20X Magnification 
 
 
 
Pictures of the whole heart section were taken with an Optronics® QuantFIRE® 
XI/MacroFIRE® 2.3A camera attached to the microscope.  Corresponding software was 
used to manipulate the image to obtain the greatest contrast from the stain.  Once the 
settings for the image were set they were not changed.  It was found during research 
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conducted by Horenziak that taking the images in a gray scale allowed for better contrast 
and analysis later on.   
 The first step was to take a picture of the white background in an area near the 
heart sections, followed by a black background taken with the light source turned off.  
These images were then used to correct the background later during analysis.  Each heart 
had three photos taken of the left ventricle at random locations that did not overlap.   
 To conduct the image analysis a Molecular Devices’® software package called 
Metamorph® (version 7.6) was used.  The Background and Shading Correction function 
was used to correct uneven intensity on all images due to staining irregularities.  This 
required taking both the white and black background images along with the image being 
analyzed and running it through the Background and Shading Correction function.  The 
new “corrected” image became the image that was used to conduct all analysis.  Using a 
control mouse the Color/Intensity threshold selection tool was used to determine the 
threshold levels that allowed distinction between the background and cell tissue which 
where, 0-252 (see Figure 5).   
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Figure 5.  Threshold Selection of Total Cell Area 
 
 
Figure 6.  Threshold and IMA Selection of Nuclei
 
 
Next a range of threshold values and Area/Shape filter parameters from the Integrated 
Morphometry Analysis (IMA) tool kit were determined to allow for the counting of 
nuclei (see Figure 6).  The Area filter was set to only select highlighted areas consisting 
of areas from 50-800 pixels total.  The Shape filter was also set to select highlighted areas 
which conformed to a circular shape match of .250 to 1.00.  These values were based on 
measurements of nuclei in a control mouse.  The threshold values for the nuclei varied 
between slides due to inconsistencies in staining intensity and nuclei locations.  This 
required adjustment of the threshold values mouse by mouse to ensure proper selection of 
nuclei.  Finally, the total number of objects was exported to Excel™ using the Object tab 
in IMA tool kit.  Next, the total area of the cell tissue was determined using the values 
stated above and then exported to Excel™ in the same manner as the nuclei data.  The 
average cell size was computed as the number of pixels per nuclei.  The values were 
averaged and compared using statistical techniques described later.  
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Brain Natriuretic Peptide Methods 
Brain Natriuretic Peptide Staining Methods 
 Brain natriuretic peptides are commonly released after a cardiac insult and its 
presence is a good indicator of heart damage.  Unstained slides from AML with fixed 
heart tissue were first de-paraffined by soaking the slides in xylene for five minutes 
twice.  This was followed by a rehydration sequence which took the slides from 100% 
ethyl alcohol down to 70% over a 24 minute period.  The slides were then rinsed in 
0.01M phosphate buffered saline solution (PBS), twice.  Then the slides were placed in a 
0.15% hydrogen peroxide solution for 15 minutes and washed in PBS (standard washing 
was conducted three times).  Following this the slides were blocked using normal goat 
serum for one hour prior to the addition of the primary antibody solution.  The primary 
antibody solution consisted of rabbit/anti-rat antibodies and was obtained from Bachem 
AG® and was diluted to a ratio of 1/500, antibody to blocking solution.  The slides were 
maintained at room temperature for one hour and transferred to a 4
o
C storage container 
overnight.  The following morning the slides were washed in PBS and then the second 
antibody was placed on the slide tissue for 35 minutes.  The second antibody was a 
goat/anti-rabbit solution obtained from Vectastain
tm 
and was diluted to a ration of 1/500, 
antibody to blocking solution.  The slides were then washed in PBS and the reagent A+B 
solution from the Elite
®
 Vectastain
tm
 ABC stain kit (rabbit IgG) was added to the tissue 
for one hour.  The slides were then washed using a nickel buffer solution three times and 
then stained for ten minutes.  The staining solution was a 3-3’-Diaminobenzidine 
tetrahydrochloride (DAB) tablet crushed and dissolved in the nickel buffer solution.  The 
slides were then washed in PBS and dehydrated in ethyl alcohol of increasing 
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concentrations from 70% to 100%.  Finally they were cover slipped and allowed to dry 
before being analyzed using a microscope.  
Brain Natriuretic Peptide Analysis Methods 
 The BNP stained slides were analyzed using a slightly modified version of a 
protocol that was used by Horenziak.  The slides were viewed under the same microscope 
and pictures taken with the same camera as the H&E tissue.  The same software was used 
to manipulate the image to obtain the greatest contrast from the stain, but unlike the H&E 
these images were taken in color.  Again, once the settings for the image and light 
settings were set they were not changed.  Background images in light and dark settings 
were taken in the same manner as the H&E slides.  Each heart section was completely 
photographed, which required approximately four to six screen shots each.   
 The image correction process was the same as the H&E tissues and like them the 
“corrected” image was then analyzed.  To conduct the image analysis a Molecular 
Devices’® software package called Metamorph® (version 7.6) was used.  The 
Background and Shading Correction function was used to correct all images to correct 
uneven intensity of the images due to staining irregularities.  This required taking both 
the white and black background images along with the image being analyzed and running 
it through the Background and Shading Correction function.  The new “corrected” image 
became the image that was used to conduct all analysis.   
 Once all the images for each heart section were corrected a selection tool was 
used to trace sections from each image which when combined with the other sections 
selected, outlined the whole heart section. The selection of all the cell tissue and BNP 
stained tissue was accomplished using the Threshold Analysis Tool.  The threshold values 
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used to select the BNP for each slide were slightly different due to variations of the stain 
concentrations for each slide.  The threshold values for the tissue were conducted in the 
same manner as that for the BNP stained tissue but were set to include all heart tissue.  
 Using the regional statistics tab, the total number of pixels in the traced region for 
both BNP and total cell area were calculated for each picture.  This information was 
recorded and then combined with all picture sections in Excel™ to determine the total 
BNP and tissue pixel areas for the complete heart section.  A ratio of BNP to total cell 
area was then calculated to normalize the data for statistical comparison. 
Electrocardiography Methods 
Data Collection Procedure 
 Electrocardiography is an excellent non-invasive method to observe cardiac 
performance.  It was conducted on every mouse that underwent ECHOs during weeks 
three, seven, nine, and 10.  The mice were first weighed using a Denver Instruments® 
XP-500 electronic scale in the surgical suite.  After the mice were weighed they were 
placed in an anesthesia chamber and anesthetized using a forced flow 2% ISF in pure 
oxygen mixture, the anesthesia was administered via a Surgivet Anesco® Isotec 4™ 
anesthesia machine (see Figure 7).   Once the mice were knocked out, they were moved 
to observation table and placed on the isothermal pad and subjected to a constant flow of 
1% ISF for the duration of the examination.  The front two legs of the mice were spread 
and taped to the pad to help immobilize the mice.  To achieve proper contact for the two 
ECG leads the mice had their chest hair removed with Nair™ and cleaned with an 
isopropyl alcohol pad (see Figure 8).   
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Figure 7.  Mouse in Anesthesia Chamber 
             
 
Figure 8.  Application of Hair Remover to Mouse
 
 
Electrocardiography data recordings were taken, before and after, dobutamine was 
administered to the mice (via subcutaneous injection see Figure 9), and between the pre 
and post dobutamine ECHO imaging.  
 
 
 
Figure 9.  Injection of Dobutamine to Study Mouse 
 
 
 
Recordings pre and post dobutamine injection lasted approximately three to four minutes 
each.  The electrodes were attached using Schwartz micro-serrefine clips.  The first lead 
was placed below the neck line in the dorsal thoracic region near the front right leg; the 
second lead was placed in the lower left abdominal area of the mouse (see Figure 10).   
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Figure 10.  Placement of ECG Leads on Mouse 
 
 
 
The advantage of using the isothermal pad was that it did not interfere with the ECG 
recording process like the electric heating pads used in the past.  After the leads were 
placed the probe was laid on the DSI PhysioTel® receiver to allow maximum reception. 
 The ECG readings were recorded using DSI’s Dataquest A.R.T.™ (version 4.0) 
software.  Prior to recording, the probes calibration information from the manufacturer 
was inputted into the software and set to record in ECG mode and the sampling 
frequency was set to 5000 kilohertz.  The ECG recordings were taken for approximately 
six to seven minutes.  After the first two minutes the mice were injected with dobutamine 
(1mg/kg) to create a stressed state in the heart.  The ECG readouts were monitored to 
observe the onset of the dobutamine induced stress and once achieved the recordings 
continued for a few more minutes. 
Electrocardiography Analysis Method 
 All ECG recordings were analyzed using DSI’s Ponemah™ software program 
(version 4.90), and a modified version of the protocol developed by Horenziak.  The 
A.R.T. files were uploaded and converted into the software program.  Prior to beginning 
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data analysis, under the Ponemah
™
 Platform tab, data recording parameters were set to 
record, all derived data and an analysis template blank were opened.  Additionally, the 
scale was set to -0.5mV and 1.0mV to allow for the best view of the ECG recording.  
 Once the parameters was set up, the ECG recording analysis attributes values had 
to be adjusted because the predetermined QT interval for murine analysis was to long (it 
was lowered from 100 to 70 milliseconds).  After changing the QT interval the entire 
ECG tracing was analyzed.  Due to the limits of the software and the variability in the 
recording values not all P and T-waves were marked.  In order to mark the missing P and 
T-waves the software’s template analysis toolkit was used by taking a representative 
wave and adding the missing markers and reanalyzing the ECG tracing for any wave 
sections that were an 80% match (see Figures 11 and 12 for defined points on the ECG 
readout).   
 
 
 
Figure 11.  Significant Points on a Mouse ECG 
          
 
Figure 12.  Example of Marker Placement by 
Ponemah™ Software 
 
 
 
The wave analysis using templates was done until the entire tracing was marked properly.  
The subjective nature of placing the missing markers required that standardization of 
P-wave start
P-wave end
Q-wave peak
R-wave peak
S-wave peak
S-wave end
T-wave peak
T-wave end
P-wave start
P-wave end
Q-wave peak
R-wave peak
S-wave peak
S-wave end
T-wave peak
T-wave end
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wave placements be adhered to.  The placement of the P-wave was defined as the small 
inverted u shaped wave prior to the QRS complex.  Due to differences between T-waves 
in humans and mice the T-wave markings had to be further defined.  The peak of the T-
wave was defined as the maximum deflection from the iso-electric line after the end of 
the S-wave (see Figure 11).  However, in stressed conditions and some pre stressed drug 
treated mice the peak of the T-wave was defined as the last saddle point prior to the 
tracing returning to the iso-electric line due to an inversion of the T-wave.  The end of the 
T-wave was defined in all cases as the point where the tracing returned to the iso-electric 
line.  If the T-wave had not returned to the iso-electric line prior the start of the P-wave 
(thus merging with the P-wave) the end of T-wave was defined as the point just prior to 
the start of the P-wave (see Figure 13). 
 Once the tracing was marked it was reviewed to find a uniform 30 second interval 
pre and post dobutamine.  These 30 second intervals were then reviewed beat-by-beat to 
remove any beats that could not be marked properly (caused mainly by movement or 
breathing (see Figure 14).  These marks were removed and any beats that could be 
marked and were missed were marked at this time.  After this the Derived data was then 
converted and saved as an Excel™ file. 
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Figure 13.  Example of ST Segment Merging with 
the P wave 
        
 
Figure 14.  Example of ECG Degradation Due to 
Respiration 
 
 
 
Once the data was converted to Excel™ format, several corrections to the data had to be 
made; adjustments to the RR interval were corrected to compensate for removed beats; 
QT interval, ST segment, and T interval were corrected for heart rate.  Ponemah™ 
defines the RR interval as the interval from one marked R-wave to the next R-wave; as 
such if one beat (and thus the R-wave) was deleted due to a breath (or other anomaly) the 
corresponding RR interval would be twice the normal value.  To correct the RR interval 
were beats had been removed the RR value was divided by the number of beats removed 
to correct it.  After the RR interval was corrected a corrected QT interval was then 
calculated (relabeled as QTc) using the derived QT interval and a method which 
normalizes the interval to 100 beats per minute (Mitchell, et al. 1998).  This is required 
due to high resting heart rates of mice. 
                                                                                                                     (1) 
 To analyze abnormalities in ST segments and T intervals (from T peak to T end) 
novel methods had to be created due to the lack of a true ST segment in mice, unlike that 
of humans.  It has been noted that in mice there is an early peaking in the T-wave (which 
P-wave start
T-wave end
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is also merged with the end of the S-wave), (Horenziak 2010).  To overcome these issues 
Van Acker et al. developed a method by which depressions and elevations of the ST 
segment (which is defined as the distance from end of S to the T peak) can be measured 
(van Acker, et al. 1996, Horenziak 2010).  The T interval is defined as the difference 
between, T peak and T end, accordingly the following formula were used to determine 
STc and Tc. 
                                                              
               
       
                                             (2) 
                                                                     
      
       
                                                    (3) 
 
 
 
Figure 15.  Parameters Used in and Derived from the Equations (1, 2, and 3) 
 
 
 
Unlike in the study by Horenziak, the T peak was used in place of the QTAN due to large 
numbers of inverted T-waves (see Figure 15).  Using all the data from the 30 second 
intervals, averages were obtained for the following parameters (QRS, QTc, T peak to T 
end, Tc, STc) for each group for statistical analysis.   
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Echocardiography Methods 
 ECHOs were done on every mouse studied during the various weeks in vivo 
studies were conducted.  The methods used to conduct the measurements and analyze 
them were exactly the same as those used in the study by Horenziak.  However they were 
unable to be used due system recording and copying failures.  
Statistical Methods  
 All data was analyzed using JMP® 8, and checked for normality, outliers, and 
equal variances prior to ANOVA and t testing.  After the data was checked for normality, 
outliers, and equal variances the appropriate statistical test was conducted to determine if 
significance existed.  All comparisons were checked for significance using a α of 0.05.  
All graphs show the standard error unless otherwise noted.  
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IV. Results 
Results of Body and Tissue weights Analysis 
 Mouse body weights showed marked differences based on whether they were 
exposed to sarin or not.  Sarin mice were approximately two grams lighter than those not 
exposed throughout the study with a significance at an α of 0.05 (see Figure 16).   
 
 
 
Figure 16.  Body Weight Measurements from the Atropine Study 
 
 
 
Another noticeable trend was after the atropine/2PAMCL injection of the control mice 
there was weight loss of around one gram in the group (although not significantly less).  
There was no loss of weight in the control mice over the same time period.  The 
control+atropine mice did recover the lost weight by week seven when compared to the 
control mice (see Figure 17).  There was also a slight loss of weight in the sarin treated 
mice after the second injection; however, it was not significant at the 0.05 level.  There 
was also no difference in body weight in the first four days between the sarin and 
sarin+atropine groups.  However, by week seven the sarin+atropine mice showed much 
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lower body weight than the sarin group, but it was not significant at the 0.05 level (p = 
0.054), (see Figure 18). 
 
 
 
Figure 17.  Comparison of Control and 
Control+Atropine/2PAMCL groups Body Weight      
 
Figure 18.  Comparison of Sarin and 
Sarin+Atropine/2PAMCL groups Body Weights 
 
 
 
 In the β adrenergic drug therapy study there was a significant difference between 
the isoproterenol and the propranolol treatment group during week nine at the 0.05 level 
(see Figure 19).  Body weights of the week 10 control mice from the Horenziak were 
taken and compared to the week nine and 11 body weights of the β adrenergic drug 
therapy study (the mice from the Horenziak study were treated in the same manner as the 
mice in this study).  The control body weights averaged 38.22g ± 1.25g the continued 
lower body weight of sarin treated mice to control mice was still observed at both weeks 
nine and 11.  At the time of sacrifice the sarin+propranolol group’s body weight was 
found to be significantly lower than both the other β adrenergic drug therapy groups (p = 
0.0001 (iso) and 0.002 (saline), see Table 3, Appendix A). 
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Figure 19.  β adrenergic drug therapy study Body Weight Comparisons 
 
 
 
 Heart weights were normalized to mice body weights (HW/BW) and analyzed to 
compare overall heart size.  The mice in the atropine study showed no significance 
between any of the treatment groups versus the control group (α = 0.05, see Table 2).   
 
 
                  Table 2.  Atropine Study HW/BW Ratios 
  Atropine Study HW/BW Ratio 
  Control Sarin Conrol+A Sarin+A 
Average 4.75 4.98 5.08 5.13 
SEM 0.11 0.20 0.19 0.16 
  
 
 
Additionally, there was no significance between any of the treatment groups (F prob = 
0.8546).  The overall trend in the atropine study mice, while not significant, shows a 
slight increase in the ratio of HW/BW from control, sarin, control+atropine/2PAMCL, 
sarin+atropine/2PAMCL (see Figure 20).  The β adrenergic drug therapy study mice 
groups had no control group from this study, so the control group (sacrificed at week 10) 
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from the study done by Horenziak was used for comparison.  Each treatment group 
(saline, isoproterenol, propranolol) showed significantly higher ratios versus the control 
group at the 0.05 level (p = 0.0334, 0.0014, 0.0078).  There was also a significant 
difference between the isoproterenol group (5.58 ± .32) and the saline and propranolol 
groups (4.52 ± 0.04, 4.70 ± 0.07), (F prob = 0.0018).  Additionally, there was no 
noticeable affect by the propranolol treated mice compared to the saline treated mice (p = 
0.75). 
 
 
 
Figure 20.  HW/BW Ratios for the Atropine and β Adrenergic Drug Treatment Studies 
 
 
 
Results of Cell Size Analysis 
 The atropine study group showed significant increases in cell size of all 
treatments versus the control at the 0.05 level (see Figure 21).  Additionally an one-way 
ANOVA between the treatment groups showed a significant difference between sarin 
only and those treated with atropine/2PAMCL (F prob = 0.0014).  
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Figure 21.  Atropine Study Cardio Myocyte Size Results 
 
 
 
 When compared to the Atropine study the β adrenergic drug therapy study shows a trend 
to larger cell size.  Due to slight differences between analysis techniques in this study and 
Horenziak’s, his week 10 H&E control data could not be compared with data from the β 
adrenergic drug therapy study.  The β adrenergic drug therapy study showed a decrease in 
the cell size of the isoproterenol (339µm
2
 ± 12 µm
2
) treated mice versus the saline 
(383µm
2
 ± 5 µm
2
) treated mice (p = 0.0296).  Additionally, there was a trend showing 
reduced cell size in the propranolol group versus the saline treated group (see Figure 22).  
Examples of the cell sizes can be seen in the pictures in Appendix C.  
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Figure 22.  β Adrenergic Drug Therapy Cardio Myocyte Size 
 
 
  
Results of ECG Analysis 
 The results of the ECG analysis are twofold; first, the actual changes in QTc, STc, 
and Tc intervals pre and post dobutamine stress testing and second, the changes in T-
wave morphology pre and post dobutamine stress testing.  Of the two, the T-wave 
morphology provides the most meaningful indicators of the possible remodeling that was 
occurring and the extent.  The week three ECG recordings showed a trend for larger 
percent differences in the sarin treated mice versus control mice for QTc and Tc intervals, 
however only the QTc difference was significantly different (p = 0.049).  There was also 
a noticeable decrease in the STc segment in both groups (see Figure 23).  
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Figure 23.  ECG Results from Week 3 
 
 
 
At week seven the sarin and control+atropine/2PAMCL groups showed a decrease in the 
percent differences of the QTc intervals versus the control (ChiSq = 0.005 and 0.045).  
The STc segments for the treatment groups were lower than the control groups, however; 
they were not statistically significant at the 0.05 level.  Additionally, the percent 
difference of the Tc segment from the control group was larger than all three treatment 
groups, significantly so, compared to the sarin and sarin+atropine/2PAMCL groups 
(ChiSq = 0.049 and 0.022), (see Figure 24).  
 
 
 
Figure 24.  ECG Results from Week 7 
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At week nine all mice were essentially sarin treated mice as defined by study protocol.  
After dobutamine stress testing large numbers of mice began showing signs of T-wave 
inversion.  All mice that showed T-wave inversion had larger percent differences for 
QTc, STc, and Tc, compared to the STc depressed mice (p = 0.07, 0.10, 0.07 
respectively), (see Figure 25).  
 
 
  
Figure 25.  Comparison Between Mice with and without T-Wave Inversion at Week 9 
 
 
 
The ECG results for week 11 (after two weeks of drug treatment) showed significance in 
the QTc segment difference at the 0.05 level for all groups (saline, isoproterenol, 
propranolol) versus the control (ChiSq = 0.025, 0.004, and 0.029).  There was no 
difference found between the STc segment percent differences, however, the 
isoproterenol and propranolol groups did show significantly lower values versus the 
control for the Tc segment (ChiSq = 0.004 and 0.01), (see Figure 26).  
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Figure 26.  ECG Results from Week 11 
 
 
 
Additional analysis of the T-waves on the ECG readouts showed increased levels of T-
wave depression and inversion in the sarin exposed mice versus the controls in weeks 
three and seven.  Comparison of week nine and week 11 T-waves showed the effects of 
the drug treatments on the mice.  The isoproterenol treated mice showed increased heart 
stress, pre-dobutamine, while the propranolol treated mice showed no T-wave inversions 
after treatment compared to four out of seven mice at week seven (Appendix B has 
examples of T-wave morphology in the ECG readings). 
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Figure 27.  Comparison of T-Wave Variations at Week 3, 7, 9, and 11 
 
 
 
Comparison of the week seven and nine sarin groups shows a continued increase in the 
morphology of the T-wave post dobutamine injection with little to no change in pre 
dobutamine indicators for sarin treated mice (see Figure 28). 
 
 
 
Figure 28.  Weeks 7 and 9 T-wave Comparisons 
 
 
 
Results of BNP Analysis 
 BNP staining was done at the end of this study.  Initial qualitative examination of 
the slides showed increases in BNP levels for sarin and atropine/2PAMCL treated mice 
which was later confirmed by analysis of the atropine study group (see Figure 29).   
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Figure 29.  Examples of BNP perfusion in Control, Control+Atropine/2PAMCL, and Sarin+Atropine/2PAMCL 
mice ventricles 
  
 
 
There were also possible increases in the week 11 mice BNP levels in the sarin+saline 
mice and decreases in the isoproterenol and propranolol treated mice versus the control.  
The ratio of BNP to total cell area showed significant differences between the 
atropine/2PAMCL treated mice (both control and sarin) versus the control (p = 0.028 and 
0.0001 respectively), (see Figure 30).    
 
 
 
Figure 30.  Results of BNP Analysis from the Atropine Study 
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There was even a significant difference between the sarin+atropine/2PAMCL and sarin 
treated mice (p = .0001).  Comparison of BNP levels in the β adrenergic drug treatment 
groups were not significant at the 0.05 level (see figure 31).  
 
 
 
Figure 31.  Results of BNP Analysis form the Β adrenergic drug therapy study 
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IV. Discussion 
Introduction 
 Results of previous studies have shown that a single exposure to asymptomatic 
levels of sarin nerve agent can lead cardiac remodeling.  This study looked to determine 
whether the standard treatment for nerve agent exposure, (atropine/2PAMCL) could 
protect the heart from long term remodeling.  Additionally sarin exposed mice were 
treated with β receptor agonists and antagonists to look at their effects on cardiac 
performance and morphology.    
Atropine/2PAMCL Study Discussion 
 Change in body weight can be an indicator of any number of harmful conditions.  
There was a significant difference in body weights between the control and sarin exposed 
mice (28.17g ± .33 vs. 25.78g ± .34).  The atropine/2PAMCL treated groups showed 
decreases of approximately 1g in body weight post treatment (Table 4, Appendix A).  By 
week three the two different sarin groups had both regained their weight.  This effect of 
weight loss after sarin exposure has been well documented (Bide & Risk, 2004; Grauer, 
et al., 2008; Shih, et al., 2006).   All groups showed a continued increase in body weight 
into week seven.  Due to the steady (there was no sudden increase in body weight 
noticed) weight gain over time after the initial exposures and treatments, it is not believed 
to be a factor in the noticed cardiac performance differences between groups. 
 Heart weight is an important indicator of overall performance and heart health.  
There was a noticeable upward trend in HW/BW ratios from control, sarin, 
control+atropine/2PAMCL, sarin+atropine/2PAMCL (Table 3, Appendix A), which 
cannot be explained by cholinergic insult.  While noticeable, the upward lacked 
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significance at the 0.05 level due to large variances which were caused by the small 
sample size.  All physiological data collected from the sarin group up to week seven were 
consistent with previous findings which show induced long term hypertrophy in mice 
after sarin exposure.  The physiological results showed that the atropine/2PAMCL 
treatment had more profound markers for hypertrophy than the sarin data, which was not 
expected.   
 Along with slightly larger HW/BW ratios the cell size analysis of the 
atropine/2PAMCL groups also showed that the cardio myocytes of the two groups are 
significantly larger than both the control and sarin groups at week seven (Table 3, 
Appendix A).  This increase in cell size is also an indicator of hypertrophy (Takeda, et al. 
2010, Harada, et al. 1997).  Analysis of BNP levels in heart tissue is used as an indicator 
of cardiac insult and possible damage.  The results of the BNP analysis also point to 
greater cardiac insult due to atropine/2PAMCL treatment.  The higher levels of BNP in 
both groups treated with atropine/2PAMCL (34.2% ± 5.6 and 24.4% ± 2.1) versus the 
control (14.7% ± 2.4) support this.  Of interest is the difference even between control and 
sarin atropine/2PAMCL groups which suggests a possible additive affect of the two 
agents.  
 ECG’s are used to identify changes in the electrical impulse propagation in the 
heart.  Anomalies in the recordings allow for in vivo observation of cardiac performance.  
The ECG data in the atropine study shows markers which are indicative of hypertrophy in 
both sarin and atropine/2PAMCL treated mice.  The atropine/2PAMCL groups showed 
an increase in QTc intervals which is a sign of possible hypertrophy (Abraham, et al. 
2001).  The Tc segment changes were also noted which is due to the presence of ST 
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depression and inverted T-waves after dobutamine stressing.  Two-thirds of the 
atropine/2PAMCL nearly two-thirds of the sarin treated mice showed ST point 
depression or T-wave inversion, which are both signs of ischemia in mice (Lambiase, et 
al. 2003, Chu, et al. 2001, Stoller, et al. 2007, Tomai, et al. 1999).  Ischemia has also 
been shown to be an indicator of hypertrophy due to inability of the coronary circulatory 
system to adequately supply blood to hypertrophic cardiac muscle tissue (Smits and 
Smits 2004).  These results of mice treated with atropine/2PAMCL might be the result of 
long term damage to the muscarinic receptors caused by the atropine treatment, which 
caused an increase in heart rate at the time of treatment (possibly stressing the heart).  
β Adrenergic Drug Therapy Study Discussion 
 Treatment of various heart conditions (including hypertrophy) involve the use of 
drugs which either stimulate or block the normal function of β adrenergic receptors.  By 
looking at the effects of these drugs on sarin exposed mice insights into therapeutic 
treatments can be gained.  The mice in the β adrenergic drug therapy study were treated 
with a 0.4LD50 dose of sarin and experienced similar changes in weight loss and gain as 
the sarin mice in the atropine study.  After the administration of the drug treatments at 
week nine all groups showed increases in body weight by week 11, however overall body 
weights were still significantly lower than the week 10 control mice, these results are 
consistent with the previous studies results (Horenziak 2010).   
 After normalization of the heart weights from week 11, using the body weight, 
and comparing them to the week 10 control mice, all treatment groups showed 
significantly larger HW/BW ratios than the control mice (see Table 3, Appendix A).  The 
isoproterenol group also showed significantly larger HW/BW ratios than either treatment 
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group (see Table 3, Appendix A), this was expected as long term treatment with 
isoproterenol is known to induce hypertrophy (Ramos, et al. 2003, Hoffman 2001).  The 
propranolol group showed significant change versus the control, but not against the sarin 
group.  This lack of hypertrophic reversal is most likely due to the low level of 
propranolol used (20mg/kg), a study in rats showed hypertrophic reversal at doses of 40 
and 80 mg/kg body weight, but not at 10mg/kg (Marano, et al. 2002).   Cell size analysis 
showed lower cell size in the isoproterenol and propranolol groups versus the saline 
treated mice.  Only the isoproterenol group showed statistical significance (see Table 5, 
Appendix A).  The smaller size of the isoproterenol group is most likely due to increased 
cell division of the cardio myocytes (Nadal-Ginard, et al. 2003).;  This assumption was 
unable to be confirmed.  The decrease in the propranolol is likely the beginning of 
possible hypertrophic reversal but again was unable to be verified.   
 The BNP analysis showed similar results as the cell size analysis.  The BNP 
levels were lower in both the isoproterenol and propranolol versus the saline group (but 
for different reasons).  The isoproterenol results are most likely due to the increase in 
cardio myocytes which would result in a decrease in cardiac stress and thus a decrease in 
BNP levels.  The decrease in propranolol BNP levels is likely due to the anti-
hypertrophic effects of the drug which leads to lower cardiac stress and lower BNP 
levels. 
 At week nine there were noticeable differences between mice which underwent T-
wave inversion and those which showed ST depression post dobutamine stressing.  While 
none of the differences (QTc, STc, Tc) were significant at the 0.05 level (p = 0.07, 0.11, 
0.07), the mix between the two affected the statistical comparisons of the segment 
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intervals.  The week 11 data for the saline treated group showed similar results as the 
weeks seven and nine sarin mice, which are all indicative of hypertrophy (see Table 6, 
Appendix 4).  Looking at the mice T-waves pre and post dobutamine stressing shows the 
lack of anomalies pre dobutamine stress testing, and their presence after dobutamine 
stressing.  The isoproterenol treated mice showed almost exclusive T-wave inversion pre 
and post dobutamine stressing which indicates that the heart was already stressed (which 
is expected after treatment with isoproterenol).  This initial stressed state of the hearts 
resulted in no change of the QTc interval and reversed trends in STc and Tc differences 
after the injection of dobutamine.  The results show that after treatment with 
isoproterenol the mice lacked any cardiac reserve and failed to respond to the dobutamine 
stimulus.  The propranolol treated mice showed no T-wave inversion (it was present at 
week nine), but instead showed complete ST depression after dobutamine stress testing.  
ST depression is a sign of remodeling in heart tissue and may indicate the beginnings of 
hypertrophic reversal from the propranolol treatment.  There was no difference in the Tc 
interval in propranolol treated mice and a small increase in the QTc interval, but they 
showed an increase in the STc interval.   
Limitations of the Study 
 Due to the inability to conduct ECHO recordings on all mice during the data 
collection weeks, not all mice underwent dobutamine stress testing in weeks three and 
seven.  This resulted in a lack of complete ECG and body weight data for these weeks, 
preventing meaningful timeline analysis using these parameters.  This incomplete testing 
of all groups at weeks three and seven also lowered the overall n for each group, thus 
lowering the ANOVA statistical power.  Another limitation of this study is the lack of 
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baseline data for the ECG recordings for each mouse before sarin exposure.  Obtaining an 
ECG baseline, would have allowed for more in-depth analysis on the timeline of cardiac 
changes. 
 Additional limitations of the studies were that there was only one treatment (dose) 
level of atropine/2PAMCL and propranolol in the studies.  Without being able to test 
multiple dose levels it was not possible to determine if their effects could be beneficial at 
different dose levels to either prevent or treat hypertrophy in cardio myocytes after 
exposure to sarin at asymptomatic doses.   
 This study looked at BNP levels in the cardiac tissue post sacrifice.  There are 
assay kits which measure BNP levels in blood plasma in mice.  Utilizing these kits pre 
and post sarin exposure would have allowed for a more complete analysis of the onset of 
cardiac remodeling. 
Future Work 
 To more accurately determine if the atropine/2PAMCL treatment could be 
beneficial in treating possible low dose exposure to sarin, a range of treatment doses 
should be tested.  The same study should be done with propranolol to determine if larger 
doses per kg of body mass would result in reversal of the hypertrophic effects of sarin.  
Further studies should also continue to look at the mechanism of action of sarin on the 
cardiac system.  Additional studies of possible treatment protocols should also be 
explored to see if there is one that can effectively prevent or treat the cardiac remodeling 
caused by low dose sarin exposure.  Additionally, the use of BNP levels in the blood 
should be analyzed to look at levels over time to see if they change over time and 
correspond to other markers of cardiac remodeling. 
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Conclusion 
 All data obtained during the two studies reinforced the findings by Horenziak, 
that acute low dose sarin exposure causes hypertrophy in the hearts of mice.  The 
standard antidote treatment dose of atropine/2PAMCL (10 and 25 mg/kg) in rodents is 
not effective in preventing hypertrophy in cardiac tissue of mice, in fact, the data 
collected on the mice treated in this manner showed stronger markers of hypertrophy than 
the sarin treated mice.  The increased stress on the heart from isoproterenol and increased 
cardiac load of sarin mice after dobutamine injection indicate that the low dose sarin 
exposure does not damage the β1 adrenoreceptor cascade.  This suggests that it would be 
possible to treat the hypertrophic effects caused by sarin with propranolol possibly 
reversing the hypertrophy if proper dose levels can be determined. 
 The ECG recordings of these studies continued to show the insidious nature of 
low dose sarin exposure by appearing normal prior to dobutamine stress testing.  These 
results are of extreme interest to the military community for several reasons.  First, most 
early warning equipment employed by the military are designed and employed to detect 
levels of CWA that pose a direct threat to life or limb.  These levels are higher than 
symptomatic doses, thus, they would not be able to detect nerve agents at the 
asymptomatic dose levels used in this experiment.  Second, based on the normal cardiac 
output that is present at a non-stressed state, personnel exposed to asymptomatic levels 
would show no issues during normal activities, such garrison or non-field operations.  
However, this would quickly change during periods of high cardiac output, i.e., physical 
fitness training, deployment operations, and field operations, which, could affect heart 
performance or result in heart failure of the Soldier.  Third, current post deployment 
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physicals occur far before these symptoms would present themselves and annual 
physicals do not include a heart stress test unless there are extenuating circumstances.  It 
is therefore extremely important that any possible (no matter how minor) exposure to 
nerve agents be reported and be included in Soldiers’ medical records to ensure proper 
medical care in the future.  These physical concerns of heart performance, holes in the 
current medical screening process, and detection limitations of CWA’s demonstrate the 
need for further examination of low dose toxicological effects of sarin. 
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Appendix A: Data Tables 
 
 
Table 3. HW/BW Ratio Data 
  Atropine Study HW/BW Ratio 
  Control Sarin Conrol+A Sarin+A 
Average 4.75 4.98 5.08 5.13 
SEM 0.11 0.20 0.19 0.16 
     
  β adrenergic drug therapy  HW/BW Ratio 
  Control* Sarin Iso Prop 
Average 4.02 4.52 5.58 4.70 
SEM 0.25 0.04 0.32 0.07 
* Indicates data used from a separate study 
 
 
Table 4.  Body Weight Data 
 
 
 
 
 
 
 
3/4/10 3/5/10 3/6/10 3/8/10 week 3 week 7 Sacrifice
Average 28.17 27.96 27.92 27.82 28.88 31.05 31.36
SEM 0.33 0.32 0.35 0.22 0.54 0.96 0.83
Average 25.78 25.75 25.31 25.42 26.34 30.68 29.25
SEM 0.34 0.36 0.31 0.33 0.46 0.75 0.45
Average 28.32 28.03 26.92 26.96 No Data 31.00 31.68
SEM 0.29 0.26 0.49 0.87 No Data 0.65 0.54
Average 25.37 25.56 25.16 25.25 No Data 27.17 27.86
SEM 0.34 0.35 0.45 0.34 No Data 0.72 0.53
Atropine Study Groups Body Weights
control
sarin
control+A
sarin+A
3/4/10 3/5/10 3/6/10 3/8/10 week 7 week 9 week 11 Sacrifice
Average 26.24 25.99 25.57 25.79 29.02 29.20 31.61 31.43
SEM 0.30 0.21 0.25 0.27 0.44 0.56 0.53 0.43
Average 25.70 24.91 24.65 24.34 28.38 29.83 32.28 32.83
SEM 0.35 0.44 0.67 0.91 0.41 0.89 0.45 0.41
Average 24.76 24.64 24.17 24.85 28.75 28.56 29.70 28.59
SEM 0.62 0.75 0.78 0.44 0.95 1.07 0.69 0.61
Sarin + 
propranolol
Drug Treatment Study Groups Body Weights
Sarin + 
saline
Sarin + 
isoprterenol
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Appendix A: Data Tables 
 
 
Table 5.  Cardio Myocyte Cell Size Data 
  Atropine Study Groups Cell Sizes (µm²) 
  Control Sarin Control+Atropine/2PAMCL Sarin+Atropine/2PAMCL 
Average 221 280 321 324 
SEM 15 10 9 6 
 
 
 
 
 
Table 6.  T-Wave Comparison Data 
 
 
 
 
 
 
 
Sarin + Saline Sarin + Isoproterenol Sarin + Propranolol
Average 383 339 360
SEM 5 12 14
β adrenergic drug therapy Cell Sizes (µm²)
pre d post d pre d post D
normal 7 4 6 0
ST depressed 0 2 0 5
T wave inversion 1 2 1 2
Control Sarin
Week 3 Atropine Study T-Wave Types
pre d post d pre d post D pre d post d pre d post d
normal 6 3 2 1 16 7 5 3
ST depressed 0 1 0 1 1 8 1 2
T wave inversion 0 2 3 3 2 4 1 2
Control Sarin+AtropineControl+Atropine Sarin
Week 7 Atropine Study T-Wave Types
pre d post d pre d post D pre d post d pre d post d
normal 6 1 7 1 4 0 17 2
ST depressed 0 2 0 4 1 3 1 9
T wave inversion 1 4 0 2 2 4 3 10
Combined
Week 9 Drug Treatment Study T-Wave Types
Sarin+Saline Sarin+Isoproterenol Sarin+Propranolol
Wave Type pre d post d pre d post D pre d post d
normal 5 2 0 0 2 0
ST depressed 0 2 1 1 3 5
T wave inversion 1 2 5 5 0 0
Sarin+Saline Sarin+Isoproterenol Sarin+Propranolol
Week 11 Drug Treatment Study T-Wave Types
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Appendix A: Data Tables 
 
 
Table 7.  Atropine Study ECG Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
QRS pre QRS post Tpe pre Tpe post HR pre HR post QTc pre QTc post STc2 pre STc2 post Tc2 pre Tc2 post % diff QTc % diff STc2 % diff Tc2 % diff HR
Average 14.88 14.40 24.99 29.46 454.26 548.90 51.14 55.41 17.57 14.81 21.27 27.90 0.09 -0.11 0.36 0.22
STD 3.33 2.80 6.12 7.17 49.28 53.36 4.44 6.04 5.24 3.75 4.90 6.04 0.16 0.30 0.37 0.14
Average 15.46 15.14 24.73 32.39 395.79 537.25 47.17 58.55 14.76 13.59 19.84 30.61 0.25 -0.08 0.59 0.38
STD 1.69 1.95 5.76 3.61 54.36 40.71 4.91 5.34 3.27 5.66 3.73 3.46 0.11 0.37 0.37 0.20
Average 15.36 15.59 21.43 28.13 446.68 577.46 44.36 57.30 12.81 14.59 18.29 27.41 0.31 0.14 0.56 0.31
STD 1.04 1.53 5.91 7.19 52.25 47.02 4.71 4.28 1.20 6.38 4.24 6.28 0.21 0.52 0.47 0.17
Average 15.93 15.93 27.84 29.72 492.39 550.80 51.35 54.38 11.62 10.65 25.33 28.49 0.06 0.00 0.18 0.13
STD 1.92 1.98 8.43 3.82 63.07 46.27 5.41 7.14 6.07 6.61 8.48 4.19 0.10 0.52 0.21 0.09
Average 14.89 14.97 25.74 26.92 460.61 590.66 49.35 54.08 13.75 12.61 22.58 26.63 0.11 -0.10 0.28 0.29
STD 1.30 1.08 6.72 4.99 42.38 54.10 5.67 2.87 2.86 4.99 6.10 4.81 0.17 0.29 0.54 0.14
Average 15.22 15.27 26.41 28.06 470.64 578.07 49.98 54.17 13.08 11.99 23.45 27.21 0.10 -0.07 0.25 0.24
STD 1.55 1.44 7.13 4.73 50.32 53.93 5.52 4.43 4.09 5.44 6.82 4.59 0.15 0.37 0.46 0.14
Average 15.27 15.28 25.80 26.54 464.84 580.18 50.05 53.67 13.96 12.88 22.68 25.78 0.07 -0.09 0.17 0.26
STD 1.21 1.08 5.51 3.54 50.32 59.98 3.22 4.40 3.98 5.40 5.14 3.33 0.09 0.26 0.18 0.14
Average 14.67 14.76 30.21 32.01 414.93 540.88 52.00 57.67 14.74 13.33 25.09 30.38 0.11 -0.04 0.21 0.30
STD 0.85 0.64 1.98 4.72 46.73 69.28 3.34 2.44 2.28 7.05 2.19 5.43 0.10 0.51 0.17 0.06
Average 15.83 15.80 26.23 25.13 490.02 588.78 49.40 53.18 11.87 13.04 23.30 24.53 0.09 0.07 0.09 0.21
STD 1.38 1.39 11.07 7.15 69.49 70.79 11.30 9.43 5.28 6.70 8.70 5.62 0.16 0.38 0.15 0.14
Control 
Week 3
Sarin 
Week 3
Control 
Week 7
Sarin 
Week 7
Iso+Prop
+Sal 
Week 7Combine
d Sarin 
Sarin 
Minus T 
Control+
Atro 
Week 7Sarin+Atr
o Week 7
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Table 8.  β adrenergic drug therapy study ECG Data 
 
 
 
 
 
 
 
 
 
QRS pre QRS post Tpe pre Tpe post HR pre HR post QTc pre QTc post STc2 pre STc2 post Tc2 pre Tc2 post % diff QTc % diff STc2 % diff Tc2 % diff HR
Average 15.83 16.01 29.76 31.25 404.68 589.32 51.63 59.67 14.24 12.87 24.41 30.94 0.16 0.02 0.28 0.46
STD 1.38 2.07 4.56 9.03 30.36 28.99 4.90 6.16 3.29 6.64 3.79 8.84 0.15 0.73 0.39 0.11
Average 16.25 15.69 20.39 31.34 458.99 636.80 46.87 57.50 14.96 9.19 17.71 32.21 0.24 -0.37 0.96 0.40
STD 1.48 2.08 6.09 9.51 52.70 41.80 5.40 5.00 3.28 7.50 5.08 9.59 0.17 0.55 0.83 0.18
Average 16.06 15.87 27.74 31.71 468.32 613.58 53.76 58.04 15.19 10.00 24.34 32.01 0.10 -0.33 0.48 0.32
STD 2.46 2.55 10.29 7.81 45.64 30.14 7.36 9.02 4.27 7.32 8.44 7.69 0.25 0.49 0.60 0.12
Average 16.05 15.86 25.97 31.43 444.00 613.23 50.75 58.40 14.80 10.69 22.15 31.72 0.17 -0.22 0.58 0.39
STD 1.75 2.13 8.13 8.36 50.61 37.99 6.40 6.64 3.48 6.99 6.62 8.32 0.19 0.60 0.67 0.15
Average 15.56 15.26 26.87 28.07 463.46 626.07 51.64 55.80 14.62 11.65 21.38 28.59 0.09 -0.16 0.33 0.36
STD 1.61 1.77 9.21 6.20 43.70 35.90 5.50 7.77 2.95 5.49 9.75 5.90 0.14 0.43 0.43 0.14
Average 16.58 16.51 24.97 35.13 422.59 599.11 49.77 61.27 14.99 9.63 18.97 35.17 0.26 -0.29 0.84 0.43
STD 1.83 2.39 7.11 9.14 50.97 36.78 7.44 3.69 4.15 8.52 8.33 9.48 0.20 0.76 0.79 0.15
Average 17.48 18.76 28.15 29.76 430.60 541.34 53.89 57.40 15.32 11.26 23.78 28.36 0.09 -0.16 0.24 0.27
STD 0.83 1.73 2.09 7.05 35.95 33.55 4.41 7.44 4.78 3.43 1.04 7.10 0.16 0.31 0.35 0.08
Average 16.77 16.87 33.96 29.80 555.60 557.08 62.14 62.05 13.68 17.48 32.29 28.29 0.00 0.28 -0.14 0.00
STD 1.65 1.74 8.04 9.48 64.66 62.12 1.72 2.03 3.78 5.54 6.05 7.93 0.02 0.17 0.13 0.02
Average 16.75 16.32 48.08 40.81 384.05 503.28 63.26 66.09 11.89 14.12 38.06 37.16 0.06 0.19 0.00 0.32
STD 3.57 3.84 12.12 5.65 54.16 46.47 9.71 4.98 3.51 4.45 8.15 3.60 0.10 0.15 0.15 0.16
Average 16.49 17.33 21.19 27.17 395.22 553.55 4.42 5.66 13.78 14.19 17.11 25.84 0.30 0.34 0.47 0.40
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Appendix B: ECG Pre and Post Dobutamine Recordings 
 
 
 
Figure 32.  Control Mouse ECG Trace Before 
Dobutamine Injection 
The end of S rises above the iso-electric point and the T-
wave tail falls below the iso-electric point before 
returning (marking the iso-electric relaxation time). Note: 
as depicted TC is not corrected by the (RR/100)
1/2. 
 
Figure 33.  Control Mouse ECG Trace After 
Dobutamine Injection 
The end of S rises above the iso-electric point.  The STC 
segment and TC segments do not change markedly. 
 
 
 
 
Figure 34.  Sarin Mouse ECG Trace Before 
Dobutamine Injection 
The end of S rises above the iso-electric point slightly less 
than the controls (but not markedly). 
 
Figure 35.  Sarin Mouse ECG Trace After 
Dobutamine Injection Showing ST Depression 
The end of S does not rise to the iso-electric point.  The 
STC segment is slightly shortened when compared to the 
controls and TC segment is significantly lengthened. 
 
 
  
Typical End of S 
in a Mouse
STC
TC
No ST Depression
STC
TC
No ST 
Depression
STC
TC
ST Depression
STC
TC
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Appendix B: ECG Pre and Post Dobutamine Recordings 
 
 
 
 
Figure 36.  Sarin Mouse ECG Trace Before 
Dobutamine Injection 
The ST is slightly depressed.  The T-wave tail falls below 
the iso-electric point before returning. 
 
 
Figure 37.  Sarin Mouse ECG Trace After 
Dobutamine Injection Showing Severe ST Depression 
The end of S does not rise to the iso-electric point.  The 
STC segment is significantly shortened when compared to 
the controls and TC segment is significantly lengthened. 
 
 
 
Figure 38.  Isoproterenol Treated Mouse ECG 
Trace Before Dobutamine Injection 
The T-wave is already inverted and ends at the start of 
the P-wave 
 
Figure 39.  Isoproterenol Treated Mouse ECG 
Trace After Dobutamine Injection 
There was no change in the T-wave even after 
dobutamine injection 
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Appendix C:  
H&E Stained Slide Picture Examples Used for Cell Size Analysis 
 
 
 
 
Figure 40.  Photos of Each Treatment Group from the Atropine Study 
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Appendix C: 
H&E Stained Slide Picture Examples Used for Cell Size Analysis 
 
 
 
 
Figure 41.  Photos From the β Adrenergic Drug Treatment Study 
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Appendix D: Masson’s Trichrome Photos 
 
 
 
Figure 42.  Masson's Trichrome Photos from Atropine Study 
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Appendix D: Masson’s Trichrome Photos 
 
 
 
Figure 43.  Masson's Trichrome Photos from β Adrenergic Drug Treatment Study 
 
 
 
 
 
63 
 
Bibliography 
Abou-Donia, Mohamed B. "Organophosphorus Ester-Induced Chronic Neurotoxicity." 
 Archives of Environmental Health, 2003: 484-497. 
 
Abraham, S., N. Oz, R. Sahar, and T. Kadar. "QTc Prolongation and Cardiac Lesions 
 Following Acute Organophosphate Poisoning in Rats." Proc.West 
 Pharmacol.Soc., 2001: 185 - 186. 
 
Anderson, M., D. Moore, and D. F. Larson. "Comparison of Isoproterenol and 
 Dobutamine in the Induction of Cardiac Hypertrophy and Fibrosis." Perfusion, 
 2008: 231- 235. 
 
Atkielski, Anthony. Wikimedia Commons. January 13, 2007. 
 http://en.wikipedia.org/wiki/File:SinusRhythmLabels.svg (accessed 01 12, 2010). 
 
Bide, R. W., and D. J. Risk. "Inhalation Toxicity in Mice Exposed to Sarin (GB) for 20 - 
 720 Min." J. Appl. Toxicol., 2004: 459 - 467. 
 
Brain natriuretic peptide. December 7, 2010. 
 http://en.wikipedia.org/wiki/Brain_natriuretic_peptide (accessed February 4 , 
 2011). 
 
Brown, Joan H, and Palmer Taylor. "Muscarinic Receptor Agonists and Antagonists." In 
 Goodman & Gilman's; The Pharmacological Basis of Therapeutics, by Joel G 
 Hardman and Lee L Limbird, 155-174. New York: McGraw-Hill, 2001. 
 
CDC. Agency for Toxic Substances and Disease Registry. 10 16, 2007. 
 http://www.atsdr.cdc.gov/csem/cholinesterase/pam_medications.html (accessed 
 October 10, 2010). 
 
CDC. Background Document on Gulf War-Related Research for the Health Impact of 
 Chemical Exposures During the Gulf War: A Research Planning Conference. 
 Conference, Atlanta GA: CDC (Center for Disease Control and Prevention), 
 1999, 55. 
Chavesa, Alysia A., Spencer J. Dech, Tomohiro Nakayama, Robert L. Hamlin, John 
 Anthony Bauera, and Cynthia A. Carnes. "Age and Anesthetic Effects on Murine 
 Electrocardiography." Life Sciences, 2003: 2401 - 2412. 
 
Chu, Victor, Jose M Otero, Orlando Lopez, James P Morgan, Ivo Amende, and Thomas 
 G Hampton. "Method for non-invasively recording electrocardiograms in 
 conscious mice." BMC Physiology, 2001. 
 
Committee on Gulf War and Health: Updated Literature Review of Sarin. "Gulf War and 
 Health: Updated Literature Review of Sarin." In Gulf War and Health: Updated 
64 
 
 Literature Review of Sarin, 14 - 17. Washington DC: National Academy of 
 Sciences, 2004. 
 
Couzin, Jennifer. "VA Advisers Link Gulf War Illnesses to Neurotoxins." Science 
 Magazine, October 1, 2004: 26 - 27. 
 
Daly, Annemarie L., Oscar A. Linares, Marla J. Smith, Mark R. Starling, and Mark A. 
 Supiano. "Dobutamine Pharmacokinetics During Dobutamine Stress 
 Echocardiography." The American Journal of Cardiology, 1997: 1381 - 1386. 
 
Eroschenko, Victor P. diFiore's Atlas of Histology with Functional Correlations (11th 
 ed.). Baltimore MD: Lippincott Williams & Wilkins, 2008. 
 
Ferguson, Charles D. "WMD Terrorism." In Combatibg Weapons of Mass Destruction; 
 The Future of International Nonproliferation Policy, by Nathan E. Busch and 
 Daniel H. Joyner, 24-44. Athens: University of Georgia Press, 2009. 
 
Geiter, Henry B. E-Z ECG Rhythm Interpretation. F.A. Davis, 2006. 
Goetze, Jens Peter, Birgitte Georg, Henrik L. Jorgensen, and Jan Fahrenkrug. "Chamber-
 Dependent Circadian Expression of Cardiac Natriuretic Peptides." Regulatory 
 Peptides (Uncorrected Proof), 2009: 1 - 6. 
 
Grauer, Ettie, et al. "Single Whole-Body Exposure to Sarin Vapor in Rats: Long-term 
 Neuronal and Behavioral Deficits." Toxicology and Applied Pharmacology, 2008: 
 265 - 275. 
 
Harada, Masaki, Hiroshi Itoh, Osamu Nakagawa, and Yoshihiro Ogawa. "Significance of 
 Ventricular Myocytes and Nonmyocytes Interaction During Cardiocyte 
 Hypertrophy." Circulation, 1997: 3737 - 3744. 
 
Hartley, C. J., L. H. Michael, and M. L. Entman. "Noninvasive Measurement of 
 Ascending Aortic Blood Velocity in Mice." Am J Physiol Heart Circ Physiol, 
 1995: H499 - H505. 
 
Hartley, Craig J., George E. Taffet, Anilkumar K. Reddy, Mark L. Entman, and Lloyd H. 
 Michael. "Noninvasive Cardiovascular Phenotyping in Mice." ILAR Journal, 
 2002: 147 - 158. 
 
He, Quan, Ding Wang, Xiao-Ping Yang, Oscar A Carretero, and Margot C. LaPointe. 
 "Inducible regulation of human brain natriuretic peptide promoter in transgenic 
 mice." American Journal Physiology Heart Circulation Physiology, 2001: H368-
 H376. 
 
Hoffman, Brian B. "Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor 
 Antagonists." In Goodman & Gilman's: The Pharmacological Basis of 
65 
 
 Therapeutics, by Joel G. Hardman and Lee E. Limbird, 215-268. McGraw Hill, 
 2001. 
 
Hoffman, Brian B., and Palmer Taylor. "Neurotransmission: The Autonomic and Somatic 
 Motor Nervous Systems." In Goodman & Gilman's: The Pharmacological Basis 
 of Therapeutics, by Joel G. Hardman and Lee E. Limbird, 115-154. McGraw Hill, 
 2001. 
 
Horenziak, Michael W. "Low Dose Sarin Leads to Murine Cardiac Dysfunction." Air 
 Force Institute of Technology, 2010. 
 
Jokanovic, M., Melita Kosanovic, and Matej Maksimovic. "Interaction of 
 Organophosphorus Compounds with Carboxylesterases in the Rat." Archives of 
 Toxicology, 1996: 444 - 450. 
 
Kawakami, Rika, Yoshihiko Saito, Ichiro Kishimoto, and Masaki Harada. 
 "Overexpression of Brain Natriuretic Peptide Facilitates Neutrophil Infiltration 
 and Cardiac Matrix Metalloproteinase-9 Expression After Acute Myocardial 
 Infarction." Circulation, 2010: 3306 - 3312. 
 
Kerins, David M., Rose M. Robertson, and David Robertson. "Drugs used for the 
 Treatment of Myocardial Ischemia." In Goodman & Gilman's: The 
 Pharmacological Basis of Therapeutics, by Joel G. Hardman and Lee L. Limbird, 
 843-870. McGraw Hill, 2001. 
 
Kramer, Klass, Lewis Kinter, Brian P. Brockway, Hans-Peter Voss, Rene Remie, and 
 Bert L. M. Van Zutphen. "The Use of Radiotelemetry in Small Laboratory 
 Animals: Recent Advances." Contemporary Topic by American Association for 
 Laboratory Animal Science (American Association for Laboratory Animal 
 Science) 40, no. 1 (2001). 
 
Lambiase, Pier D., Richard J. Edwards, Michael R. Cusack, Clifford A. Bucknall, Simon 
 R. Redwood, and Michael S. Marber. "Exercise-Induced Ischemia Initiates the 
 Second Window of Protection in Humans Independent of Collateral 
 Recruitment." J Am Coll Cardiol, 2003: 1174 - 1182. 
 
Li, Bin, Meghan Sedlacek, Indumathi Manoharan, and Rathnam Boopathy. 
 "Butyrylcholinesterase, Paraoxonase, and Albumin Esterase, but not 
 Carboxylesterase, are Present in Human Plasma." Biochemical Pharmacology, 
 2005: 1673 - 1684. 
 
London, Barry. "Cardiac Arrhythmias: From (Transgenic) Mice to Men." Journal of 
 Cardiovascular Electrophysiology, 2001: 1089 - 1091. 
 
66 
 
London, Barry. "Natriuretic Peptides and Cardiac Hypertrophy." Journal of the American 
 College of Cardiology, 2006: 506-507. 
 
Marano, Giuseppe, Sergio Palazzesi, Antonello Fadda, Alessandro Vergari, and Alberto 
 U. Ferrari. "Attenuation of aortic banding-induced cardiac hypertrophy by 
 propranolol is independent of â-adrenoceptor blockade." Journal of Hypertension, 
 2002: 763-769. 
 
Marrs, Timothy C. "Toxicology of Organophosphate Nerve Agents." In Chemcial 
 Warfare Agents Toxicology and Treatment, by Timothy C. Marrs, Robert L. 
 Maynard and Frederick R. Sidell, 191 - 223. West Sussex, England: John Wiley 
 & Sons Ltd., 2007. 
 
McDonough, John H., and James A., Jr Romano. "Health Effects of Low-Level Exposure 
 to Nerve Agents." In Chemical Warefare Agents: Chemistry, Pharmacology, 
 Toxicology, and Therapeutics, by James A. Romano, Luckey, Brian J. Jr and 
 Harry Salem, 71-96. Boca Raton: CRC Press, 2008. 
 
Meridian Medical Technologies, Inc. "PRALIDOXIME CHLORIDE INJECTION 
 (AUTO-INJECTOR)." Columbia, MD, October 2003. 
 
Mertes, Horst, Stephen G. Sawada, Thomas Ryan, and Douglas S. Segar. "Symptoms, 
 Adverse Effects, and Complications Associated With Dobutamine Stress 
 Echocardiography: Experience in 1118 Patients." Circulation, 1993: 15 - 19. 
 
Mitchell, Gary F., Andreas Jeron, and Gideon Koren. "Measurement of Heart Rate and 
 Q-T Interval in the Conscious Mouse." Am J Physiol Heart Circ Physiol, 1998: 
 747-751. 
 
Morris, Mariana, Mary P. Key, and Vera Farah. "Sarin Produces Delayed Cardiac and 
 Central Autonomic Changes." Experimental Neurology, 2007: 110 - 115. 
 
Nadal-Ginard, Bernardo, Jan Kajstura, Annarosa Leri, and Piero Anversa. "Myocyte 
 Death, Growth, and Regeneration in Cardiac Hypertrophy and Failure." 
 Circulation Research, 2003: 139-150. 
 
New York State Department of Health Bureau of Emergency Medical Services. "Use of 
 Mark I Kits." New York, February 2003. 
 
Parkinson, Andrew. "Biotransformation of Xenobiotics." In Essentials of Toxicology, by 
 Curtis D. Klaassen and John B. III Watkins, 71-97. McGraw Hill, 2003. 
 
67 
 
Persian Gulf War Illnesses Task Force. "Khamisiyah: A Historical Perspective on 
 Related Intelligence." GulfLINK. 04 02, 1997. 
 http://www.gulflink.osd.mil/cia_wp/ (accessed 02 09, 2010). 
 
Ramos, Kenneth S., Russell B. Melchert, Enrique Chacon, and Daniel Acosta. "Toxic 
 Responses of the Heart and Vascular System." In Essentials of Toxicology, by 
 Curtis D., Watkins, John B. Klaassen, 266-287. McGraw Hill, 2003. 
 
Roth, David M., James S. Swaney, Nancy D. Dalton, Elizabeth A. Gilpin, and John Ross 
 Jr. "Impact of Anesthesia on Cardiac Function During Echocardiography in 
 Mice." Am J Physiol Heart Circ Physiol, 2002: 2134 - 2140. 
 
Salem, Harry, Andrew L., Jr Terney, and Jeffery J. Smart. "Brief History and Use of 
 Chemical Warfare Agents in Warfare." In Chemical Warfare Agents: Chemistry, 
 Pharmacology, Toxicology, and Therapeutics, by , James A., Jr Romano, Brian J. 
 Lukey and Harry Salem, 1-20. Boca Raton: CRC Press, 2008. 
 
Scott, Nicola J.A., Leigh. J. Ellmers, John G. Lainchbury, and Nobuyo Maeda. "Influence 
 of Natriuretic Peptide Receptor-1 on Survival and Cardiac Hypertrophy During 
 Development." Biochimica et Biophysica Acta, 2009: 1175 - 1184. 
 
Shaheen, Joseph, David Luria, Marc W. Klutstein, David Rosenmann, and Dan Tzivoni. 
 "Diagnostic Value of 12-lead Electrocardiogram during dobutamine 
 echocardiographic studies." American Heart Journal, 1998: 1061 - 1064. 
 
Shih, T.-M., S. W. Hulet, and J. H. McDonough. "The Effects of Repeated Low-Dose 
 Sarin Exposure." Toxicology and Applied Pharmacology, 2006: 119 - 134. 
 
Sidell, F. R., and J. Borak. "Chemical warfare agents: II. Nerve agents." Annals of 
 Emergency Medicine, 1992: 865 – 871. 
 
Smits, Anke M., and Jos F.M. Smits. "Ischemic Heart Disease: Models of Myocardial 
 Hypertrophy and Infarction." Drug Discovery Today: Disease Models, 2004: 273 
 - 274. 
 
Stein, Adam B., Sumit Tiwari, Paul Thomas, and Greg Hunt. "Effects of Anesthesia on 
 Eechocardiographic Assessment of Left Ventricular Structure and Function in 
 Rats." Basic Res Cardiol, 2005: 28 - 41. 
 
Stoller, Douglas, Rahul Kakkar, Matthew Smelley, and Karel Chalupsky. "Mice Lacking 
 Sulfonylurea Receptor 2 (SUR2) ATP-Sensitive Potassium Channels are Resistant 
 to Scute Cardiovascular Stress." Journal of Molecular and Cellular Cardiology, 
 2007: 445 - 454. 
 
68 
 
Swoap, Steven J., J. Michael Overton, and Graham Garber. "Effect of Ambient 
 Temperature on Cardiovascular Parameters in Rats and Mice: a Comparative 
 Approach." Am J Physiol Regulatory Integrative Comp Physiol, 2004: 391 - 396. 
 
Takeda, Norifumi, Ichiro Manabe, Yuichi Uchino, and Kosei Eguchi. "Cardiac 
 Fibroblasts are Essential for the Adaptive Response of the Murine Heart to 
 Pressure Overload." The Journal of Clinical Investigation, 2010: 254 - 265. 
 
Tan, Tze Ping, Xiao-Ming Gao, Mark Krawczyszyn, and Xinheng Feng. "Assessment of 
 Cardiac Function by Echocardiography in Conscious and Anesthetized Mice: 
 Importance of the Autonomic Nervous System and Disease State." J Cardiovasc 
 Pharmacol, 2003: 182 - 190. 
 
Taylor, Palmer. "Anticholinesterase Agents." In Goodman & Gilman's: The 
 Pharmacological Basis of Therapeutics, by J. G. Hardman, L. E. Limbird and A. 
 G. Gilman, 175-191. New York NY: McGraw Hill Companies, Inc., 2001. 
 
Tomai, Fabrizio, Filippo Crea, Luigi Chiariello, and Pier A. Gioffrè. "Ischemic 
 Preconditioning in Humans : Models, Mediators, and Clinical Relevance." 
 Circulation, 1999: 559 - 563. 
 
USAMRID. "Nerve Agents." In Medical Management of Chemical Casualties 
 Handbook, 122-156. Aberdeen Proving Grounds: U.S. Government, 2007. 
 
van Acker, Saskia A.B. E., Klaus Kramer, Joop A. Grimbergen, Wim J. F. van der Vijgh, 
 and Aalt Blast. "Doxorubicin-Induced Chronic Cardiotoxicity Measured in Freely 
 Moving Mice." Cancer Chemother Pharmacol, 1996: 95-101. 
 
Wehrens, Xander H.T., Susanne Kirchhoff, and Pieter A. Doevendans. "Mouse 
 Electrocardiography: An Interval of Thirty Years." Cardiovascular Research, 
 2000: 231 - 237. 
 
Weissman, Nell J., Michael W. Levangie, J. Luis Guerrero, Arthur E. Weyman, and 
 Michael H. Picard. "Effect of B-blockade on Dobutamine Stress 
 Echocardiography." American Heart Journal, 1996: 698 - 703. 
 
Wiesmann, Frank, Jan Ruff, Stefan Engelhardt, and Lutz Hein. "Dobutamine-Stress 
 Magnetic Resonance Microimaging in Mice : Acute Changes of Cardiac 
 Geometry and Function in Normal and Failing Murine Hearts." Circulation 
 Research, 2001: 563 - 569. 
 
Yasuno, Shinji, Satoru Usami, Koichiro Kuwahara, Michio Nakanishi, and Yuji Arai. 
 "Endogenous Cardiac Natriuretic Peptides Protect the Heart in a Mouse Model of 
 Dilated Cardiomyopathy and Sudden Death." Am J Physiol Heart Circ Physiol, 
 2009: 1804 - 1810. 
REPORT DOCUMENTATION PAGE 
Form Approved 
OMB No. 074-0188 
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and 
maintaining the data needed, and completing and reviewing the collection of information.  Send comments regarding this burden estimate or any other aspect of the collection of information, including 
suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, 
Suite 1204, Arlington, VA  22202-4302.  Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to an penalty for failing to comply with a collection of 
information if it does not display a currently valid OMB control number.   
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 
1. REPORT DATE (DD-MM-YYYY) 
24-03-2011 
2. REPORT TYPE  
Master’s Thesis 
3. DATES COVERED (From – To) 
Sept 2010 – Mar 2011 
4.  TITLE AND SUBTITLE 
 
Immediate and Delayed Drug Therapy Effects on Low Dose Sarin Exposed Mice 
Myocardial Performance 
5a.  CONTRACT NUMBER 
5b.  GRANT NUMBER 
 
5c.  PROGRAM ELEMENT NUMBER 
6.  AUTHOR(S) 
 
 
Miller, Joshua T. MAJ, USA 
5d.  PROJECT NUMBER 
 
5e.  TASK NUMBER 
5f.  WORK UNIT NUMBER 
7. PERFORMING ORGANIZATION NAMES(S) AND ADDRESS(S) 
     
     Air Force Institute of Technology 
   Graduate School of Engineering and Management (AFIT/EN) 
 2950 Hobson Way 
   WPAFB OH 45433-7765 
 
8. PERFORMING ORGANIZATION 
    REPORT NUMBER 
 
AFIT/GWM/ENP/11-M03 
9.  SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 
 
Intentionally left blank 
10. SPONSOR/MONITOR’S ACRONYM(S) 
 
 
11.  SPONSOR/MONITOR’S REPORT 
NUMBER(S) 
12. DISTRIBUTION/AVAILABILITY STATEMENT 
APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED 
 
13. SUPPLEMENTARY NOTES  
 
This material is declared a work of the U.S. Government and is not subject to copyright protection in the United States. 
14. ABSTRACT  Recent studies have shown that a single asymptomatic dose exposure to the nerve agent sarin can lead to long term 
cardiac dysfunction.  This study looked at immediate and delayed treatment therapies post exposure on cardiac function.  The mice 
were studied using electrocardiography (QTc, STc, and Tc intervals) and histological techniques (hematoxylin and eosin staining and 
brain natriuretic peptide (BNP) staining).  Male C57BL/6J mice were injected with sarin (0.4LD50) and studied up to 11 weeks.  Mice 
which were given a single dose of the nerve agent treatment atropine/2PAMCL, showed significantly higher cell size and BNP levels 
than the control (p = 0.001) and increased QTc and Tc intervals, all of which are indicators of cardiac insult .  Mice which received 
drug treatments after the onset of cardiac remodeling showed increased (thus worsening) normalized heart size for isoproterenol (β 
agonist) treated mice (p = 0.0018) versus saline treated mice along with inverted T-waves pre cardiac stressing.  Propranolol (β 
blocker) treated mice showed only T-wave depression and no difference in normalized heart size versus the saline group.  These 
results suggest that standard treatment methods for nerve agent exposure are not effective in preventing long term cardiac dysfunction 
and in fact cause them.  
15. SUBJECT TERMS 
GB, sarin, low dose, beta blockers, atropine, oximes 
16. SECURITY CLASSIFICATION OF: 
Unclassified 
17. LIMITATION OF  
     ABSTRACT 
 
UU 
 
18. NUMBER  
      OF 
      PAGES 
81 
 
19a.  NAME OF RESPONSIBLE PERSON 
Charles A. Bleckmann (AFIT/ENV) 
a. REPORT 
 
U 
b. ABSTRACT 
 
U 
c. THIS PAGE 
 
U 
19b.  TELEPHONE NUMBER (Include area code) 
(937)-255-3636 
   Standard Form 298 (Rev. 8-98) 
Prescribed by ANSI Std. Z39-18 
 
Form Approved 
OMB No. 074-0188 
 
